HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is the most common subtype of breast cancer. It makes up about 70% of all breast cancer cases. HR+/HER2 ...

The C-HR+ is Toyota’s latest electric SUV to launch in Norway, where nearly all cars sold today are EVs. Toyota calls it “the perfect electric SUV for Norwegian roads,” with a spacious interior and up ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

The Toyota C-HR+ will be the car that kicks this off. And while it was unveiled in Europe with specifications only for that market for now, it seems poised to be a hit in the United States as well ...

PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the ...

At an event in Brussels last week, the world's largest automaker showed off a heavily updated bZ4X, the all-new C-HR+ and the recently released Urban Cruiser. While the cars they revealed are ...

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ metastatic breast cancer. Treatment with Bria-IMT plus check point ...

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY ...

In BriaCell’s Phase 2 clinical study in late-stage MBC, 25 of 37 patients treated with the ongoing pivotal Phase 3 Bria-IMT formulation were identified as having HR+ breast cancer. As shown in ...